The globalAnti-Ageing Drugs marketreport offers a deep analysis of the global Anti-Ageing Drugs market. It demonstrates a brief summary of industry data and key nomenclature of the market. The report has highlights well-known performers from the global market together with their contribution to the market to determine their progress within the estimated time.

The most preeminent Anti-Ageing Drugs market players are Nu Skin, BIOTIME, INC., DermaFix, Unity Biotechnology, LORAL, Frequency Therapeutics, Elysium Health Inc., Nuritas, Calico, Revision Optics, Elysium, La Roche-Posay. The global Anti-Ageing Drugs research report covers recent improvements while predicting the growth of the main players along with their market shares.

Free Access to the sample pages of the report at

The report estimates the global Anti-Ageing Drugs market volume in the earlier years. It assesses the global Anti-Ageing Drugs market on the basis of returns [USD Million] and quantity [k MT]. The study emphasizes the main constraints and devices determining the market growth. It also determines the valuation of the global Anti-Ageing Drugs market for the predicted time. The report covers the growing movements along with the key opportunities for the development of the global Anti-Ageing Drugs market.

The global Anti-Ageing Drugs market research report covers the key product category and sections Serums and supplements, Antioxidants and enzymes, Stem cells and drugs as well as the sub-sections Skin and hair, Skeletal and muscles, Age-related disorders, Others of the global Anti-Ageing Drugs market. The complete classification of the Anti-Ageing Drugs market is available in the global report related to the analytics of the restraining and supporting factors of the market.

Ask Any Kind of Query Before Purchasing the Report Here::https://www.marketresearchstore.com/report/global-anti-ageing-drugs-industry-market-2019-industry-684907#InquiryForBuying

How will this Market Intelligence Report Benefit You?

1. The report offers statistical data in terms of value (US$) and Volume (units) for the global Anti-Ageing Drugs market today and to 2026.

2. Exclusive insight into the key trends affecting the Anti-Ageing Drugs industry, although key threats, opportunities and disruptive technologies that could shape the global Anti-Ageing Drugs market supply and demand.

3. The report tracks the leading market players that will shape and impact the global Anti-Ageing Drugs market most.

4. The data analysis present in the Anti-Ageing Drugs report is based on the combination of both primary and secondary resources.

5. The report helps you to understand the real effects of key market drivers or restrainers on Anti-Ageing Drugs business.

The global Anti-Ageing Drugs market classification is based on the variety of products and end-user request sections. The market study includes the development of each section of the global Anti-Ageing Drugs market. The data summarized in the report is a collection of variant manufacturer bodies to approximate the growth of sections in future time.

The global Anti-Ageing Drugs market report evaluates the market development across foremost zonal sections. It is divided on the basis of topography as Europe, North America, Latin America, Asia Pacific, and Middle East & Africa. The report embraces the spirited circumstances obtainable in the global Anti-Ageing Drugs market.

Read Detailed Index of full Research Study at::https://www.marketresearchstore.com/report/global-anti-ageing-drugs-industry-market-2019-industry-684907

Read more from the original source:
Global Anti-Ageing Drugs Industry Market Growth Graph To Demonstrate Inclination Towards Positive Axis By 2026 - The Courier

Graft Versus Host Disease (GVHD) Epidemiology

According to the National Cancer Institute (NCI), Graft versus host disease (GVHD) is a disease caused when cells from a donated stem cell graft attack the normal tissues of the transplant patient. Symptoms include jaundice, skin rash or blisters, a dry mouth, or dry eyes. GVHD occurs when particular types of white blood cells (T cells) in the donated bone marrow or stem cells attack the host body cells because the donated cells (the graft) see the host cells as foreign and attack them.

GVHDhas two types Acute GVHDand Chronic GvHD. Acute GvHD is also known as fulminant GVHD and occurs usually in the initial 2-3 months after transplantation. Chronic GVHD occurs around 3-4 months after the transplantation has happened, and has more diverse complications. This type affects the liver, stomach, vagina, joints, lungs, gut, mouth and glands secreting mucus or saliva.

Get FREE sample copy at:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

DelveInsights Graft Versus Host Disease (GVHD) Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Graft Versus Host Disease (GVHD) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.The DelveInsight Graft Versus Host Disease (GVHD) epidemiology report gives a thorough understanding of the Graft Versus Host Disease (GVHD) disease symptoms and causes, along with the risk factors, diagnosis, pathophysiology associated with the disease, and. It also provides treatment algorithms and treatment guidelines for Graft Versus Host Disease (GVHD) in the US, Europe, and Japan. The report covers the detailed information of the Graft Versus Host Disease (GVHD) epidemiology scenario in seven major countries (US, EU5, and Japan).

Key Highlights Of The Report

As per a study by Elgaz S. et al., (2019), GVHDoccurs in 3050% of recipients and 14% of all patients suffer severe GVHDgrades 34. Chronic GVHDaffects 3070% of patients receiving allo-SCT.

As per a study by Jacobsohn and Vogelsang (n.d.) titled Acute graft versus host disease, in the United States, approximately 5,500 patients/year can develop acute GVHD and in 2003, the incidence of grade II-IV acute GVHD was roughly 3550%.

As per Orphanet, about 35%-50% of hematopoietic stem cell transplant (HSCT) recipients will develop acute Graft versus host disease (GVHD). And about 50% of patients with acute GVHD will eventually have manifestations of chronic GVHD.

Graft Versus Host Disease (GVHD) Epidemiology

Scope of the Report

Key Benefit of Graft Versus Host Disease (GVHD) Epidemiology Report

The Graft Versus Host Disease (GVHD) Epidemiology report will allow the user to

Get FREE sample copy at:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

Table of Contents

*The table of contents is not exhaustive; will be provided in the final report

Related ReportsGraft versus host disease (GVHD)- Market Insight, Epidemiology and Market Forecast -2030DelveInsight s Graft versus host disease (GVHD) Market Insights, Epidemiology and Market Forecast 2030 report provides a detailed overview of the disease and in depth understanding of historical and forecasted epidemiology.

Graft versus host disease (GVHD) Pipeline Insights, 2020Graft versus host disease (GVHD) Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Graft versus host disease (GVHD) market.

About DelveInsightDelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact usShruti Thakur[emailprotected]+91-9650213330https://www.delveinsight.com/LinkedIn | Facebook | TwitterGraft Versus Host Disease (GVHD) Epidemiology Report:https://www.delveinsight.com/sample-request/graft-versus-host-disease-gvhd-epidemiology-forecast

See original here:
Graft Versus Host Disease (GVHD) Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030 - The Market Feed

­­Orphazyme A/SInvestor news                                                                                                       No. 07/2020                                                                                                          Company Registration No. 32266355

Read the rest here:
Orphazyme establishes U.S. headquarters in Chicago as the company prepares for commercialization

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO) today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for Marzeptacog alfa (activated) – or MarzAA, the Company’s subcutaneously (SQ) administered next-generation engineered coagulation Factor VIIa (FVIIa) for the treatment of episodic bleeding in subjects with Hemophilia A or B with inhibitors that will enter a pivotal Phase 3 study CRIMSON 1 this month.

See the rest here:
Catalyst Biosciences Receives FDA Fast Track Designation for Subcutaneous MarzAA for the Treatment of Episodic Bleeding in Hemophilia A or B with...

BUFFALO, N.Y., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that its subsidiary, Athenex Pharmaceutical Division (APD), has launched Liquid, Ready-To-Dilute Cyclophosphamide. The product is being brought to market through APD’s co-marketing partnership with Ingenus Pharmaceuticals, LLC. APD will leverage existing commercial relationships with hospitals, integrated health systems, which include U.S. cancer centers, major distributors, and GPOs, to optimize distribution and commercial uptake of Liquid, Ready-To-Dilute Cyclophosphamide. In 2019, Athenex’s specialty pharmaceuticals business sold into nearly 2,800 oncology hospitals, critical care sites, and clinics.

Read more from the original source:
Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide

Proceeds support expanded clinical program of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity Proceeds support expanded clinical program of BST-236, a proprietary anti-metabolite enabling high-dose chemotherapy with reduced systemic toxicity

Continue reading here:
Biosight Closes $46M Series C Financing to Advance Clinical Oncology Programs

DUBLIN, Ireland, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, today announced that it will effect a 1-for-10 reverse stock split of its outstanding ordinary shares, which will be effective for trading purposes on the Nasdaq Global Select Market as of the commencement of trading on December 3, 2020.

Go here to see the original:
Nabriva Therapeutics Announces Date of 1-for-10 Reverse Stock Split

FORT LAUDERDALE, Fla., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Motus GI Holdings, Inc., (NASDAQ: MOTS) ("Motus GI" or the "Company"), a medical technology company providing endoscopy solutions that improve clinical outcomes and enhance the cost-efficiency associated with the diagnosis and management of gastrointestinal conditions, announced today a collaboration with Dr. Nirav Thosani, Director of Advanced Endoscopy, Memorial Hermann Hospital in Houston, Texas, to incorporate the Company’s Pure-Vu® System with the aim of improving efficiencies and clinical outcomes of inpatient colonoscopy procedures at Memorial Hermann Hospital, for patients who present with inadequate bowel preparation. The Memorial Hermann Hospital is a flagship hospital within the Memorial Hermann System, which is one of the largest not-for-profit health systems in Texas, owning and operating 14 hospitals.

See the original post:
Motus GI and Memorial Hermann Hospital Partner to Improve its Colonoscopy Efficiencies

CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function.

Go here to read the rest:
Wave Life Sciences Announces Appointment of Jonathan Rosin as Chief Human Resources Officer

OREM, Utah, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a provider of diverse products and services for the biotechnology, pharmaceutical, and transportation industries, announced a patent has been granted by the United States Patent Office for an ultracold shipping and storage container for transportation by air that uses liquid nitrogen technology for cooling.

Originally posted here:
COVID-19 Vaccine Capable Air Transportation System Patent Awarded to Reflect Scientific for its Liquid Nitrogen Temperature-controlled Cooling and...

SPRING HOUSE, Pa., Dec. 02, 2020 (GLOBE NEWSWIRE) -- SteroTherapeutics, LLC, a biopharmaceutical company developing new treatments for patients with rare diseases announced today the signing of a Cooperative Research and Development Agreement (CRADA) with the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health (NIH), to complete a Phase 2 clinical trial to determine the safety, efficacy, and dosage regimen for a non-androgenic analogue of dehydroepiandrosterone (DHEA) in the treatment of the manifestations of Cushing syndrome (also referred to as Cushing’s syndrome) including metabolic syndrome and fatty liver disease which is found in up to 25% of adult Cushing syndrome patients.

Original post:
SteroTherapeutics, LLC signs CRADA Agreement with NIH to Develop a Novel Treatment for Cushing Syndrome Patients

Conference Call and Webcast Scheduled for December 9, 2020, 4:30 pm ET

Go here to read the rest:
Enzo Biochem to Report First Quarter 2021 Financial Results on Wednesday, December 9

Read more here:
Single-Dose Radiation Therapy At Time Of Lumpectomy Helps Breast Cancer Patients Overcome Treatment Challenges During Pandemic

Appointment strengthens leadership team ahead of tebipenem HBr’s potential commercialization Appointment strengthens leadership team ahead of tebipenem HBr’s potential commercialization

Read more:
Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer

LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors, effective November 30, 2020.

Continue reading here:
Artelo Biosciences Announces Appointment of Senior Pharmaceutical Executive Gregory R. Reyes, M.D., Ph.D., to Board of Directors

MORRISVILLE, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 6,000,000 shares of the Company’s common stock (the “Offering”) at a price to the public of $61.90 per share. Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the selling stockholders in the Offering. The Offering is expected to close on December 3, 2020, subject to customary closing conditions.

Read more here:
Syneos Health Announces Pricing of Secondary Offering of Common Stock

WOBURN, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that Meghna Malik, Ph.D., Senior Director, will present at the 4th CRISPR AgBio Congress which is being held December 1-3, 2020 as a virtual event.

Read the original:
Yield10 Bioscience Researcher Dr. Meghna Malik to Present at the 4th CRISPR AgBio Congress 2020 Virtual Event

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsed/refractory multiple myeloma on December 5, 2020 via a live webinar at 11:00 AM Pacific Time/2:00 PM Eastern Time.

See the rest here:
Allogene Therapeutics Announces Webinar to Review Initial ALLO-715 Phase 1 Data on December 5, 2020

MELBOURNE, Australia, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Molecular diagnostics company Genetic Technologies Ltd (ASX: GTG; NASDAQ: GENE, the ‘Company’), announced today that they have entered into a three-year partnership agreement with mental health company, Taliaz, for the distribution rights of their PREDICTIX products in Australia, New Zealand and the USA (“Agreement”).

Visit link:
Genetic Technologies Secures US and ANZ Distribution Rights for PREDICTIX

The partnership launches RoosterBio’s first international platform with off-the-shelf working cell banks and hMSC bioprocess media products in Asia The partnership launches RoosterBio’s first international platform with off-the-shelf working cell banks and hMSC bioprocess media products in Asia

Continued here:
RoosterBio Collaborates with Sartorius to Expand Cell and Gene Therapy Manufacturing Platform Technology into South Korea